What Measured sells, what the monthly figures include, and why the FDA record matters
Better Health Labs, Inc. operates Measured as a technology and administrative platform. Its legal documents say Measured does not itself practice medicine, manufacture drugs, compound medications, or dispense prescriptions.
Cash-pay medical evaluations are attributed to Coastal Care Medical Group entities in Florida, California, and New Jersey. Cloud Health Medical Group and state affiliates handle insurance-covered registered-dietitian services. The site does not publish a complete provider directory with state and license mapping.
The current flow begins with a two-to-three-minute questionnaire. A U.S.-licensed physician or nurse practitioner reviews the history asynchronously and may prescribe when clinically appropriate. Medication consultations do not routinely require video, while nutrition appointments use video with the camera optional.
Measured lists service in Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Minnesota, Missouri, North Carolina, New Jersey, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, and Wisconsin. Product and clinician availability can still vary by state.
The catalog advertises Wegovy, Ozempic, Zepbound, Mounjaro, compounded semaglutide, compounded tirzepatide, a lower-dose GLP-1 program, Wegovy tablets, NAD+, B12 plus MIC, glutathione, sermorelin, and oxytocin nasal spray. The normalized review does not equate each brand, dose, or program label with a new active ingredient.
Wegovy and Ozempic contain semaglutide injection, but their approved indications and insurance rules differ. This review uses one branded weight-management semaglutide-injection card for Wegovy and keeps Ozempic in the narrative. The same approach puts Zepbound on the tirzepatide weight-management card and leaves insurance-required Mounjaro in the notes.
Wegovy injection is advertised with membership from $49 and cash medication from $199 to $349 per month. The compact $248 minimum adds those lowest components. A dedicated product page and the help center instead show $99 membership, so the card is not eligible for direct ranking.
Wegovy tablets use a distinct daily oral dosage form. The homepage lists medication at $149 to $299 per month and membership from $49, producing a compact minimum of $198. The product page says the prescription goes to the patient's pharmacy, while the homepage advertises free delivery; the fulfillment route should be verified at checkout.
Zepbound is advertised with membership from $49 and cash medication from $299 to $449 per month. The compact minimum is $348. Current dedicated and help pages again show a $99 membership path, and insurance cost sharing can replace the cash drug price.
Compounded semaglutide injection starts at $119 per month and compounded tirzepatide injection starts at $219, with membership and medication included. These are starting prices rather than published dose-by-dose tables. Pharmacy, exact formula, concentration, quantity, and patient-specific need are not disclosed before intake.
The lower-dose program starts at $79 and may use weekly semaglutide or tirzepatide. It is a dosing and service tier, not a new medicine. Because the ingredient and regimen are provider selected, the $79 figure cannot be assigned reliably to either standard compounded card or averaged across them.
Measured offers NAD+ injection from $159, sermorelin injection from $149, glutathione injection from $129, and oxytocin nasal spray from $159. Each page marks the product as compounded and medication included. None publishes a complete concentration, quantity, fixed schedule, pharmacy, or evidence-supported outcome definition.
B12 plus MIC is a four-component injection containing vitamin B12, methionine, inositol, and choline. It remains editorial-only because one $149 bundle cannot be assigned cleanly to a single active ingredient for leaderboard comparison. The exact B12 form, concentration, and amounts are not shown on the public page.
The help center says cash-pay products ship directly to the home at no added charge and most patients receive medication within three to seven business days after onboarding and medical review. Insurance-covered GLP-1 prescriptions go to the patient's preferred pharmacy. Neither path guarantees stock or an exact arrival date.
Labs are not routine for every participant. A clinician may request CMP, HbA1c, lipids, TSH, or other testing based on history and treatment. Recent results can be uploaded; otherwise a Quest Diagnostics or Labcorp requisition may be issued, and the patient is responsible if insurance denies the lab claim.
Membership renews automatically at the chosen monthly, quarterly, semiannual, or annual cadence. Cancellation is available through the portal or care team and takes effect after the paid period. There are no partial refunds for an unused portion of a billing cycle.
The help center says a billing period cannot be refunded once it starts, including when side effects, intolerance, or disappointing results occur. The terms use a somewhat different trigger: fees become nonrefundable after clinician review or medication shipment. Prescription products cannot be returned once dispensed.
A six-month money-back guarantee requires at least 180 consecutive days, prompt intake and baseline labs, weekly adherence, no early refill in the final two months, at least 21 weigh-ins, a starting BMI of at least 30, less than 5% loss, and a request in the stated 30-day window. It is not an unconditional satisfaction refund.
FDA warning letter MARCS-CMS 721454 said earlier pictured labels implied Measured compounded semaglutide and tirzepatide when it did not. FDA also said same-active-ingredient marketing implied approval or safety and effectiveness evaluation for products that had not received it.
Current Measured pages now state that independent state-licensed pharmacies fill prescriptions, packaging may vary, and compounded drugs are not FDA approved or evaluated. Those observable changes should not be interpreted as an FDA closeout without a public agency record confirming one.
FDA says the shortage-based enforcement-discretion periods for semaglutide and tirzepatide injection copies have ended. Patient-specific compounding can still qualify under federal law when applicable conditions are met, but a prescriber-documented clinical difference, pharmacy identity, formulation, and route are important facts to verify.
The privacy policy distinguishes protected clinical information controlled by the treating medical group from nonclinical data controlled by Better Health Labs. It describes analytics, advertising pixels, limited session replay, payment providers, messaging vendors, laboratories, pharmacies, insurers, and AI-assisted on-device text classification.
The terms require binding JAMS arbitration for most disputes, prohibit class actions, choose California law, and cap aggregate platform liability at the greater of $500 or the amount paid to Measured in the prior twelve months. Consumers should read the operative terms before enrolling.
Intelsio selected Measured for managed Awin enrollment with a reported 10% approved-sale commission. The advertiser ID, attribution window, traffic rules, EPC, and tracking link remain pending. Commercial economics have no effect on this editorial rating.
- Nine cards consolidate a fourteen-plus-option catalog into real ingredients, routes, and regulatory categories.
- Compact brand totals include the lowest published membership and medication components, with conflicts kept in notes.
- Compounded semaglutide and tirzepatide start at $119 and $219 with medication included.
- The lower-dose $79 GLP-1 tier is not counted as another active ingredient or averaged into standard programs.
- Cash-pay prescriptions ship free, while insured brand prescriptions go to the patient's pharmacy.
- Care is asynchronous, video is not routinely required, and labs are ordered case by case.
- The legal documents identify platform, medical-group, and nutrition-billing roles.
- FDA warning letter MARCS-CMS 721454 is a material transparency and regulatory concern.
- Affiliate economics are excluded from the rating and the CTA remains untracked.